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Cardiovascular and Renal Outcomes of Renin-Angiotensin 
System Blockade in Adult Patients with Diabetes Mellitus: A 




Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used 
extensively for preventing cardiovascular and renal complications in patients with 
diabetes, but data that compare their clinical effectiveness are limited. We aimed to 
compare the effects of classes of RAS blockers on cardiovascular and renal 
outcomes in adults with diabetes. 
METHODS AND FINDINGS: 
Eligible trials were identified by electronic searches in PubMed/MEDLINE and the 
Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). 
Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary 
endpoints were cardiovascular mortality, myocardial infarction, and stroke-singly and 
as a composite endpoint, major cardiovascular outcome-and end-stage renal 
disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as 
a composite endpoint, progression of renal disease. Secondary endpoints were 
angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 
participants), with a total of 14 different regimens, were pooled using network meta-
analyses. When compared with ACE inhibitor, no other RAS blocker used in 
monotherapy and/or combination was associated with a significant reduction in 
major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval 
[CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus 
ACE inhibitor (1.32; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 
0.73-1.38). For the risk of progression of renal disease, no significant differences 
were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 
1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR 
inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65-1.57), and DR inhibitor plus ARB 
(1.18; 95% CrI 0.78-1.84). No significant differences were showed between ACE 
inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, 
myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, 
or doubling serum creatinine. Findings were limited by the clinical and 
methodological heterogeneity of the included studies. Potential inconsistency was 
identified in network meta-analyses of stroke and angina pectoris, limiting the 
conclusiveness of findings for these single endpoints. 
CONCLUSIONS: 
In adults with diabetes, comparisons of different RAS blockers showed similar 
effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. 
 
 
Compared with monotherapies, the combination of an ACE inhibitor and an ARB 
failed to provide significant benefits on major outcomes. Clinicians should discuss 
the balance between benefits, costs, and potential harms with individual diabetes 
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